Hikma Pharmaceuticals PLC is driven by a strong set of values and a clear corporate philosophy. The company puts a great emphasis on delivering high-quality and accessible medicines to patients around the world. Hikma aims to improve people's lives by providing innovative and reliable healthcare solutions. With a focus on integrity, excellence, and collaboration, Hikma prioritizes patient safety and strives for continuous improvement and growth. This commitment to superior pharmaceutical products and a patient-centric approach is what defines Hikma Pharmaceuticals PLC as a leading global pharmaceutical company.

Hikma Pharmaceuticals PLC is primarily present in the countries and regions of the United States, Europe, the Middle East, and North Africa.

Hikma Pharmaceuticals PLC has achieved significant milestones throughout its history. With a strong commitment to innovation and quality, the company has successfully expanded its global presence and product portfolio. Notably, Hikma received FDA approval for its injectable generic versions of common medications, further consolidating its position in the US market. Additionally, the company achieved a remarkable milestone in 2017 by acquiring Roxane Laboratories, enabling Hikma to enhance its product offerings and manufacturing capabilities. Furthermore, Hikma's strategic partnerships and collaborations have contributed to its continuous growth and success in the pharmaceutical industry. These accomplishments highlight Hikma Pharmaceuticals PLC's dedication to advancing healthcare and delivering high-quality pharmaceutical products worldwide.

Hikma Pharmaceuticals PLC is a renowned pharmaceutical company with a rich history and impressive background. Established in 1978, the company has grown into a global leader in developing, manufacturing, and marketing a diverse range of generic and specialty medicines. Hikma focuses primarily on critical care and injectable products, as well as branded generics, serving customers in over 50 countries. With a constant commitment to quality, innovation, and meeting patient needs, Hikma has successfully become a trusted partner for healthcare professionals worldwide. Its strong global presence, extensive product portfolio, and continuous growth reflect Hikma Pharmaceuticals PLC's dedication to improving health outcomes for people across the globe.

The main competitors of Hikma Pharmaceuticals PLC in the market include multinational pharmaceutical companies like Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Novartis AG, and GlaxoSmithKline plc.

Hikma Pharmaceuticals PLC is primarily active in the pharmaceutical industry.

Hikma Pharmaceuticals PLC operates under a diversified business model. The company focuses on developing, manufacturing, and marketing a wide range of generic and branded pharmaceutical products. With a strong presence in the MENA (Middle East and North Africa) region, Hikma also expands into other global markets such as the United States and Europe. The company's business model centers on delivering high-quality medications to meet the diverse healthcare needs of patients worldwide. Through its robust research and development efforts, strategic partnerships, and commitment to excellence, Hikma Pharmaceuticals PLC aims to contribute towards enhancing global healthcare outcomes.

P/E odnos Hikma Pharmaceuticals iznosi 871,96.

KUV kompanije Hikma Pharmaceuticals iznosi 130,87.

AlleAktien kvalitativni skor za Hikma Pharmaceuticals je 8/10.

očekivana Hikma Pharmaceuticals promet je 3,09 milijardi USD.

Dobit očekivana Hikma Pharmaceuticals je 463,63 mil. USD.

Hikma Pharmaceuticals PLC is a London-based company specializing in the development, manufacturing, and marketing of generic, specialized, and biosimilar drugs. It was founded in 1978 and is headquartered in Jordan. The company operates in over 50 countries worldwide and employs more than 8,400 people. Hikma's main business areas include generics, specialty pharmaceuticals, and injections. The generics division offers a wide range of affordable and high-quality generic medications for the treatment of various diseases such as diabetes, cancer, heart diseases, neurology, and pain. Some significant generic products offered by Hikma include Azithromycin, Cefuroxime, Omeprazole, and Praziquantel. The specialty pharmaceuticals division specializes in prescription medications for the treatment of chronic diseases such as cardiovascular diseases, respiratory diseases, immunology, and oncology. Hikma focuses on developing its own branded medicines and distributing partner products. Some products in this division include Ryaltris, a nasal spray for allergic rhinitis, and Quillichew XR, a chewing gum for the treatment of ADHD. Hikma's injection division manufactures injectable medications for the treatment of diseases such as infectious diseases, anemia, pain, and cancer. Some significant injection products include Atropine, Norepinephrine, and Penicillin. Additionally, Hikma also offers a wide range of services, including product development, manufacturing, packaging, and distribution. The company has a strong presence in the markets of the USA, Europe, and the Middle East and aims to further expand this presence. In 2020, Hikma's revenue was approximately $2.33 billion. The company is committed to further growth and strengthening its leadership position in the generic, specialized, and biosimilar drug market. Overall, Hikma's business model is focused on providing affordable and high-quality medications to improve global health. The company strives to continuously expand and enhance its portfolio and services through partnerships and acquisitions.

Hikma Pharmaceuticals isplaćuje dividendu od 0,44 USD raspoređenu preko 2 isplata u toku godine.

Hikma Pharmaceuticals isplaćuje dividendu 2 puta godišnje.

ISIN od Hikma Pharmaceuticals je GB00B0LCW083.

WKN od Hikma Pharmaceuticals je A0HG69.

Oznaka za praćenje akcija kompanije Hikma Pharmaceuticals je HIK.L.

U poslednjih 12 meseci, Hikma Pharmaceuticals je isplatio dividendu u iznosu od 0,49 USD . To odgovara dividendnom prinosu od oko 0,03 %. Za narednih 12 meseci, Hikma Pharmaceuticals će verovatno isplatiti dividendu od 0,52 USD.

Dividendski prinos od Hikma Pharmaceuticals trenutno iznosi 0,03 %.

Hikma Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima септембар, април, септембар, април.

Hikma Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0,52 USD. To odgovara dividendnom prinosu od 0,03 %.

Hikma Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Hikma Pharmaceuticals od 3. 5. 2024. u iznosu od 0,371 USD, morali ste da imate akciju u depou pre Ex-dana 21. 3. 2024..

Isplata poslednje dividende izvršena je 3. 5. 2024..

U godini 2023 kompanija Hikma Pharmaceuticals je isplatila 0,442 USD kao dividende.

Dividende od Hikma Pharmaceuticals se isplaćuju u USD.